Key statistics dashboard for Bionano Genomics, Inc. (BNGO). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome using optical genome mapping. This technology is vital for deciphering genetic variations and their functional roles.
Stock Data
| Price | $1.51 |
| Market Cap | $17M |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.40 |
| Price / Book | 0.55 |
| P/S | 0.57 |
| P/FCF | -0.85 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 47.50% |
| EBIT Margin | -105.66% |
| EBITDA Margin | -74.27% |
| Operating Margin | -106.67% |
| Net Margin | -106.58% |
Financial Health
| Current Ratio | 2.48 |
| Quick Ratio | 1.96 |
| Cash Ratio | 0.37 |
| Debt / Equity | 0.21 |
| Debt / Assets | 14.09% |
| Interest Coverage | -151.12 |
| Piotroski F-Score | 4 |
| Altman Z-Score | -14.26 |
Per-Share Data
| Revenue per share | 2.61 |
| Book Value per share | 2.74 |
| Cash per share | 0.86 |
| FCF per share | -1.77 |
| Tangible Book Value per share | 2.59 |
| Dividend per share | 0.00 |
Analyst Consensus
| Strong Buy | 0 |
| Buy | 4 |
| Hold | 3 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 7 |
| Avg rating (1-5) | 0.57 |
Related companies: AIM · BNBX · GBS · KTTA · MYNZ · NDRA · POAI
Explore sector: Healthcare · Medical - Instruments & Supplies
More sections of BNGO: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks